In fact, this specific FGFR3 mutation was also identified in cfDNA samples from a series of BC patients who were candidates for Erdafitinib (12), emphasizing that the detection of the FGFR3 mutation in plasma cfDNA could be helpful to guide targeted treatment in a non-invasive way. The gene discussed is FGFR3; the disease is breast cancer.